{"nctId":"NCT02545517","briefTitle":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","startDateStruct":{"date":"2015-10-05","type":"ACTUAL"},"conditions":["Virus Diseases","Rabies"],"count":459,"armGroups":[{"label":"Conv-R/JE Group","type":"EXPERIMENTAL","interventionNames":["Biological: Rabipur","Procedure: Blood sampling","Biological: Purified Chick-Embryo Cell Rabies Vaccine"]},{"label":"Acc-R/JE Group","type":"EXPERIMENTAL","interventionNames":["Biological: Rabipur","Procedure: Blood sampling"]},{"label":"Conv-R Group","type":"EXPERIMENTAL","interventionNames":["Biological: Rabipur","Procedure: Blood sampling"]}],"interventions":[{"name":"Rabipur","otherNames":[]},{"name":"Blood sampling","otherNames":[]},{"name":"Purified Chick-Embryo Cell Rabies Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All individuals who were randomized to a Rabies primary series vaccination for pre-exposure prophylaxis (PrEP), received the full PrEP regimen and completed the parent trial following study protocol.\n\nExclusion Criteria:\n\n* Completed the parent study without receiving the full 3 rabies vaccine doses following the assigned pre-exposure prophylaxis regimen.\n* History of exposure to suspected or confirmed rabid animal.\n* Receipt of rabies immunoglobulins, rabies post exposure prophylaxis following completion of the parent study","healthyVolunteers":true,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Serious Adverse Events (SAEs) After a Booster Dose of Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine","description":"A SAE is defined as any untoward medical occurrence that at any dose results in one or more of the following: death, is life-threatening, required/prolonged hospitalization, persistent or significant disability/incapacity, congenital anomaly/or birth defect, an important and significant medical event that may not be immediately life threatening or resulting in death or hospitalization but, based upon appropriate medical judgment, may jeopardize the participants or may require intervention to prevent one of the other outcomes listed.\n\nSafety is assessed as the number of participants reporting SAEs after a booster dose of PCEC rabies vaccine administered in this extension study, if RNVA concentrations were \\<0.5 IU/mL, following a primary series of accelerated or conventional rabies pre-exposure (PrEP) intramuscular (IM) regimen in the parent study.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their Rabies Virus Neutralizing Antibody (RNVA) Concentrations Drop Below 0.5 International Units (IU) Per Milliliter (mL) Between Day 366 and Year 3","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 3 and Year 4","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 4 and Year 5","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 5 and Year 6","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 6 and Year 7","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 7 and Year 8","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 8 and Year 9","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Who Had Their RNVA Concentrations Drop Below 0.5 IU/mL Between Year 9 and Year 10","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"RVNA Antibody Concentrations 7 Days After the Booster Dose","description":"RVNA antibody concentrations were measured in terms of Geometric Mean Concentrations (GMCs) and expressed in IU/mL. The booster dose was administered in this Extension study (conducted from Year 3 to Year 9 after the primary schedule study) only when participants had RVNA concentrations \\<0.5 IU/mL at the yearly immunogenicity check (i.e., at \"Scheduled Clinic Visit\"). Booster dose administration occurred at an approximate timepoint between 6 and 9 months from the previous \"Scheduled Clinic Visit\" during the Years 3 to 9.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"4.4","spread":null}]}]}]},{"type":"PRIMARY","title":"RVNA Geometric Mean Ratios (GMRs) 7 Days After the Booster Dose Versus Antibody Concentrations Before the Booster Dose","description":"GMR was calculated as ratio of post booster dose RVNA GMCs (7-day post booster dose) to the baseline RVNA GMCs (7 days before booster dose). The booster dose was administered in this Extension study (conducted from Year 3 to Year 9 after the primary schedule study) only when participants had RVNA concentrations \\<0.5 IU/mL at the yearly immunogenicity check (i.e., at \"Scheduled Clinic Visit\"). Booster dose administration occurred at an approximate timepoint between 6 and 9 months from the previous \"Scheduled Clinic Visit\" during the Years 3 to 9.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.6","spread":null},{"groupId":"OG001","value":"23.4","spread":null},{"groupId":"OG002","value":"19.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations Greater Than or Equal to (>=) 0.5 IU/mL, 7 Days After Booster Dose","description":"The booster dose was administered in this Extension study (conducted from Year 3 to Year 9 after the primary schedule study) only when participants had RVNA concentrations \\<0.5 IU/mL at the yearly immunogenicity check (i.e., at \"Scheduled Clinic Visit\"). Booster dose administration occurred at an approximate timepoint between 6 and 9 months from the previous \"Scheduled Clinic Visit\" during the Years 3 to 9.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"89.1","spread":null},{"groupId":"OG002","value":"98.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 3","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"78.8","spread":null},{"groupId":"OG002","value":"84.9","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 4","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":null},{"groupId":"OG001","value":"70.8","spread":null},{"groupId":"OG002","value":"76.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 5","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.1","spread":null},{"groupId":"OG001","value":"69.1","spread":null},{"groupId":"OG002","value":"73.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 6","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.9","spread":null},{"groupId":"OG001","value":"66.2","spread":null},{"groupId":"OG002","value":"66.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 7","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null},{"groupId":"OG001","value":"64.4","spread":null},{"groupId":"OG002","value":"67.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 8","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"64.1","spread":null},{"groupId":"OG002","value":"64.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 9","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3","spread":null},{"groupId":"OG001","value":"63.6","spread":null},{"groupId":"OG002","value":"64.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With RVNA Concentrations >= 0.5 IU/mL at Year 10","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":null},{"groupId":"OG001","value":"62.3","spread":null},{"groupId":"OG002","value":"62.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Rabies Virus Neutralizing Antibody Concentrations","description":"Antibody concentrations were measured in terms of GMCs and expressed in IU/mL.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null},{"groupId":"OG001","value":"1.16","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":null},{"groupId":"OG001","value":"0.73","spread":null},{"groupId":"OG002","value":"0.82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"0.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0.58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0.61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.56","spread":null},{"groupId":"OG001","value":"0.76","spread":null},{"groupId":"OG002","value":"0.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"0.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":null},{"groupId":"OG001","value":"0.72","spread":null},{"groupId":"OG002","value":"0.68","spread":null}]}]}]},{"type":"SECONDARY","title":"Reverse Cumulative Percentage for Participants With RVNA Concentrations >=0.5 IU/mL","description":"As specified in the statistical analysis plan, a graphical presentation of the Reverse Cumulative Distribution Plots for participants with RVNA concentrations \\>=0.5 IU/mL was analyzed for this outcome measure. Due to system constrains, only the reverse cumulative percentage values were reported, to depict the Reverse Cumulative Distribution Plots.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"45","spread":null},{"groupId":"OG002","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"22","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":44},"commonTop":[]}}}